Improvements to levodopa-based treatments for Parkinson’s disease

Alberto Espay, MD, MSc, University of Cincinnati, Cincinnati, OH, describes the current efforts to improve levodopa-based treatments for Parkinson’s disease. These new systems include subcutaneous levodopa infusion, subcutaneous foslevodopa infusion, subcutaneous apomorphine infusion, and an oral extended-release carbidopa-levodopa - IPX203.
Experts believe that these new approaches will extend the duration of time that these treatments are effective for. IPX203 is due for FDA review in June 2023. The subcutaneous infusions will take longer for approval but may be approved within a year. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.